149 related articles for article (PubMed ID: 38181809)
1. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS).
Siva S; Louie AV; Kotecha R; Barber MN; Ali M; Zhang Z; Guckenberger M; Kim MS; Scorsetti M; Tree AC; Slotman BJ; Sahgal A; Lo SS
Lancet Oncol; 2024 Jan; 25(1):e18-e28. PubMed ID: 38181809
[TBL] [Abstract][Full Text] [Related]
2. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
[TBL] [Abstract][Full Text] [Related]
3. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
Siva S; Ali M; Correa RJM; Muacevic A; Ponsky L; Ellis RJ; Lo SS; Onishi H; Swaminath A; McLaughlin M; Morgan SC; Cury FL; Teh BS; Mahadevan A; Kaplan ID; Chu W; Grubb W; Hannan R; Staehler M; Warner A; Louie AV
Lancet Oncol; 2022 Dec; 23(12):1508-1516. PubMed ID: 36400098
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S; Bressel M; Sidhom M; Sridharan S; Vanneste BGL; Davey R; Montgomery R; Ruben J; Foroudi F; Higgs B; Lin C; Raman A; Hardcastle N; Hofman MS; De Abreu Lourenco R; Shaw M; Mancuso P; Moon D; Wong LM; Lawrentschuk N; Wood S; Brook NR; Kron T; Martin J; Pryor D;
Lancet Oncol; 2024 Mar; 25(3):308-316. PubMed ID: 38423047
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy.
Panje C; Andratschke N; Brunner TB; Niyazi M; Guckenberger M
Strahlenther Onkol; 2016 Dec; 192(12):875-885. PubMed ID: 27778052
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
[TBL] [Abstract][Full Text] [Related]
7. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
8. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.
Siva S; Chesson B; Bressel M; Pryor D; Higgs B; Reynolds HM; Hardcastle N; Montgomery R; Vanneste B; Khoo V; Ruben J; Lau E; Hofman MS; De Abreu Lourenco R; Sridharan S; Brook NR; Martin J; Lawrentschuk N; Kron T; Foroudi F
BMC Cancer; 2018 Oct; 18(1):1030. PubMed ID: 30352550
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK.
Correa RJM; Louie AV; Staehler M; Warner A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Siva S
J Urol; 2019 Jun; 201(6):1097-1104. PubMed ID: 30741849
[TBL] [Abstract][Full Text] [Related]
10. SBRT in Localized Renal Carcinoma: A Review of the Literature.
DE LA Pinta C; Latorre RG; Fuentes R
Anticancer Res; 2022 Feb; 42(2):667-674. PubMed ID: 35093865
[TBL] [Abstract][Full Text] [Related]
11. Intratumoural renal cell carcinoma haemorrhage following stereotactic radiotherapy: a case report.
Hilleary LA; Wratten C; Siva S; Hilleary J; Martin JM
BMC Cancer; 2019 Jul; 19(1):671. PubMed ID: 31286870
[TBL] [Abstract][Full Text] [Related]
12. [German S3 guideline for renal cell carcinoma : Presentation and discussion of essential aspects for the radiation oncologist].
Müller AC; van Oorschot B; Micke O; Guckenberger M
Strahlenther Onkol; 2018 Jan; 194(1):1-8. PubMed ID: 28819766
[TBL] [Abstract][Full Text] [Related]
13. When Surgery Is Not an Option in Renal Cell Carcinoma: The Evolving Role of Stereotactic Body Radiation Therapy.
Miccio J; Johung K
Oncology (Williston Park); 2019 May; 33(5):167-73, 177. PubMed ID: 31095714
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiotherapy for Renal Cell Carcinoma: Oncological and Renal Function Outcomes.
Glicksman RM; Cheung P; Korol R; Niglas M; Nusrat H; Erler D; Vesprini D; Swaminath A; Davidson M; Zhang L; Chu W
Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):20-28. PubMed ID: 35948465
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiation therapy (SBRT) on renal cell carcinoma, an overview of technical aspects, biological rationale and current literature.
Francolini G; Detti B; Ingrosso G; Desideri I; Becherini C; Carta G; Pezzulla D; Caramia G; Dominici L; Maragna V; Teriaca MA; Bottero M; Livi L
Crit Rev Oncol Hematol; 2018 Nov; 131():24-29. PubMed ID: 30293702
[TBL] [Abstract][Full Text] [Related]
16. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture.
Thibault I; Al-Omair A; Masucci GL; Masson-Côté L; Lochray F; Korol R; Cheng L; Xu W; Yee A; Fehlings MG; Bjarnason GA; Sahgal A
J Neurosurg Spine; 2014 Nov; 21(5):711-8. PubMed ID: 25170656
[TBL] [Abstract][Full Text] [Related]
17. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose-response relationship.
Siva S; Jackson P; Kron T; Bressel M; Lau E; Hofman M; Shaw M; Chander S; Pham D; Lawrentschuk N; Wong LM; Goad J; Foroudi F
Radiother Oncol; 2016 Mar; 118(3):540-6. PubMed ID: 26873790
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases.
Kothari G; Louie AV; Pryor D; Vela I; Lo SS; Teh BS; Siva S
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S17. PubMed ID: 28917255
[TBL] [Abstract][Full Text] [Related]
19. Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma.
Yamamoto T; Kadoya N; Takeda K; Matsushita H; Umezawa R; Sato K; Kubozono M; Ito K; Ishikawa Y; Kozumi M; Takahashi N; Katagiri Y; Onishi H; Jingu K
Radiat Oncol; 2016 May; 11():72. PubMed ID: 27229710
[TBL] [Abstract][Full Text] [Related]
20. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?
Amini A; Altoos B; Bourlon MT; Bedrick E; Bhatia S; Kessler ER; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
Pract Radiat Oncol; 2015; 5(6):e589-e596. PubMed ID: 26142027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
